152 related articles for article (PubMed ID: 12902485)
1. Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells.
Pittet MJ; Rubio-Godoy V; Bioley G; Guillaume P; Batard P; Speiser D; Luescher I; Cerottini JC; Romero P; Zippelius A
J Immunol; 2003 Aug; 171(4):1844-9. PubMed ID: 12902485
[TBL] [Abstract][Full Text] [Related]
2. Decreased binding of peptides-MHC class I (pMHC) multimeric complexes to CD8 affects their binding avidity for the TCR but does not significantly impact on pMHC/TCR dissociation rate.
Dutoit V; Guillaume P; Ayyoub M; Hesdorffer CS; Luescher IF; Valmori D
J Immunol; 2003 May; 170(10):5110-7. PubMed ID: 12734357
[TBL] [Abstract][Full Text] [Related]
3. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.
Valmori D; Dutoit V; Schnuriger V; Quiquerez AL; Pittet MJ; Guillaume P; Rubio-Godoy V; Walker PR; Rimoldi D; Liénard D; Cerottini JC; Romero P; Dietrich PY
J Immunol; 2002 Apr; 168(8):4231-40. PubMed ID: 11937585
[TBL] [Abstract][Full Text] [Related]
5. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR.
Dutoit V; Rubio-Godoy V; Doucey MA; Batard P; Liénard D; Rimoldi D; Speiser D; Guillaume P; Cerottini JC; Romero P; Valmori D
J Immunol; 2002 Feb; 168(3):1167-71. PubMed ID: 11801651
[TBL] [Abstract][Full Text] [Related]
6. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
[TBL] [Abstract][Full Text] [Related]
7. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.
Dietrich PY; Le Gal FA; Dutoit V; Pittet MJ; Trautman L; Zippelius A; Cognet I; Widmer V; Walker PR; Michielin O; Guillaume P; Connerotte T; Jotereau F; Coulie PG; Romero P; Cerottini JC; Bonneville M; Valmori D
J Immunol; 2003 May; 170(10):5103-9. PubMed ID: 12734356
[TBL] [Abstract][Full Text] [Related]
8. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
[TBL] [Abstract][Full Text] [Related]
9. Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL.
Rubio-Godoy V; Dutoit V; Zhao Y; Simon R; Guillaume P; Houghten R; Romero P; Cerottini JC; Pinilla C; Valmori D
J Immunol; 2002 Nov; 169(10):5696-707. PubMed ID: 12421949
[TBL] [Abstract][Full Text] [Related]
10. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
[TBL] [Abstract][Full Text] [Related]
11. High avidity antigen-specific CTL identified by CD8-independent tetramer staining.
Choi EM; Chen JL; Wooldridge L; Salio M; Lissina A; Lissin N; Hermans IF; Silk JD; Mirza F; Palmowski MJ; Dunbar PR; Jakobsen BK; Sewell AK; Cerundolo V
J Immunol; 2003 Nov; 171(10):5116-23. PubMed ID: 14607910
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
13. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.
Maeurer MJ; Necker A; Salter RD; Castelli C; Höhn H; Karbach J; Freitag K; Neukirch C; Knuth A; Jäger E
Int J Cancer; 2002 Jan; 97(1):64-71. PubMed ID: 11774245
[TBL] [Abstract][Full Text] [Related]
14. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy.
Bredenbeck A; Losch FO; Sharav T; Eichler-Mertens M; Filter M; Givehchi A; Sterry W; Wrede P; Walden P
J Immunol; 2005 Jun; 174(11):6716-24. PubMed ID: 15905511
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.
Dutoit V; Guillaume P; Romero P; Cerottini JC; Valmori D
Cancer Immun; 2002 Jul; 2():7. PubMed ID: 12747752
[TBL] [Abstract][Full Text] [Related]
16. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
Wang Z; Turner R; Baker BM; Biddison WE
J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.
Pittet MJ; Zippelius A; Speiser DE; Assenmacher M; Guillaume P; Valmori D; Liénard D; Lejeune F; Cerottini JC; Romero P
J Immunol; 2001 Jun; 166(12):7634-40. PubMed ID: 11390521
[TBL] [Abstract][Full Text] [Related]
18. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.
Geluk A; van Meijgaarden KE; Franken KL; Drijfhout JW; D'Souza S; Necker A; Huygen K; Ottenhoff TH
J Immunol; 2000 Dec; 165(11):6463-71. PubMed ID: 11086086
[TBL] [Abstract][Full Text] [Related]
19. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
Colombetti S; Fagerberg T; Baumgärtner P; Chapatte L; Speiser DE; Rufer N; Michielin O; Lévy F
J Immunol; 2006 Jun; 176(11):6560-7. PubMed ID: 16709813
[TBL] [Abstract][Full Text] [Related]
20. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
Clay TM; Custer MC; Sachs J; Hwu P; Rosenberg SA; Nishimura MI
J Immunol; 1999 Jul; 163(1):507-13. PubMed ID: 10384155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
